You are correct. The 50 percent pps drop was due to the oral fixation of investors and analysts. They do not seem to understand that the "Holy Grail" of hep C treatment is to cure the patient, not to avoid injections of interferon.
Absolutely. This entire episode with VRUS and INHX is absurdity at it's zenith. What are the pharmas thinking buying these untested overhyped drugs? It's like the inmates have taken over the asylum.
VRTX will win in the end I have no doubt about it. They are ignored because they don't overpromise with bs cherry picked data. All they do is produce the best soc and they are making huge money right now. These other "competitors" are phantoms. The other side of the valley.